Article (Scientific journals)
Prospective, real-time monitoring of pegylated Escherichia coli and Erwinia asparaginase therapy in childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma in Belgium.
Mondelaers, Veerle; Ferster, Alina; Uyttebroeck, Anne et al.
2020In British Journal of Haematology
Peer Reviewed verified by ORBi
 

Files


Full Text
Mondelaers_2020_Prospective, real-time monitoring of Pegylated E.coli and Erwinia asparaginase therapy in childhood acute lymphoblastic leukem.pdf
Publisher postprint (583.58 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
acute lymphoblastic leukaemia; allergy; asparaginase; childhood; silent inactivation; therapeutic drug monitoring
Abstract :
[en] Asparaginase (ASNase) is an important anti-leukaemic drug in the treatment of childhood acute lymphoblastic leukaemia (ALL) and non-Hodgkin lymphoma (NHL). A substantial proportion of patients develop hypersensitivity reactions with anti-ASNase neutralising antibodies, resulting in allergic reactions or silent inactivation (SI), and characterised by inactivation and rapid clearance of ASNase. We report results of a prospective, real-time therapeutic drug monitoring of pegylated Escherichia coli (PEG-)ASNase and Erwinia ASNase in children treated for ALL and NHL in Belgium. Erwinia ASNase was given as second-line after hypersensitivity to PEG-ASNase. In total, 286 children were enrolled in the PEG-ASNase cohort. Allergy was seen in 11 2% and SI in 5.2% of patients. Of the 42 patients treated with Erwinia ASNase, 7.1% experienced allergy and 2.4% SI. The median trough PEG-ASNase activity was high in all patients without hypersensitivity. After Erwinia administration significantly more day 3 samples had activities <100 IU/l (62.5% vs. 10% at day 2 (D2)). The median D2 activity was significantly higher for intramuscular (IM; 347 IU/l) than for intravenous Erwinia administrations (159 IU/l). This prospective, multicentre study shows that monitoring of ASNase activity during treatment of children with ALL and NHL is feasible and informative. Treatment with Erwinia ASNase warrants close monitoring and optimally adherence to a 2-day interval of IM administrations.
Disciplines :
Oncology
Pediatrics
Author, co-author :
Mondelaers, Veerle
Ferster, Alina
Uyttebroeck, Anne
Brichard, Benedicte
van der Werff Ten Bosch, Jutte
Norga, Koenraad
Francotte, Nadine
Piette, Caroline ;  Université de Liège - ULiège > Département des sciences cliniques > Neuropédiatrie
Vandemeulebroecke, Katrien
Verbeke, Charlotte
Schmidt, Susanne
Benoit, Yves
Lammens, Tim
De Moerloose, Barbara
More authors (4 more) Less
Language :
English
Title :
Prospective, real-time monitoring of pegylated Escherichia coli and Erwinia asparaginase therapy in childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma in Belgium.
Publication date :
February 2020
Journal title :
British Journal of Haematology
ISSN :
0007-1048
eISSN :
1365-2141
Publisher :
Wiley, Oxford, United Kingdom
Peer reviewed :
Peer Reviewed verified by ORBi
Commentary :
(c) 2020 British Society for Haematology and John Wiley & Sons Ltd. Epub ahead of print
Available on ORBi :
since 18 February 2020

Statistics


Number of views
66 (6 by ULiège)
Number of downloads
5 (3 by ULiège)

Scopus citations®
 
12
Scopus citations®
without self-citations
9
OpenCitations
 
10
OpenAlex citations
 
20

Bibliography


Similar publications



Contact ORBi